Fig. 5
Correlation between HA receptors expression at baseline and patient response to ONCOFID-P-B™. a Percentage of tumor cells expressing each HA receptor at baseline. b-c Expression (counts/mm2) of each HA receptor at baseline according to clinical response (b) after the 12-weekly ONCOFID-P-B™ instillation of the intensive phase and (c) at the end of the 15-month study. Significantly different data are represented by *p < 0.05, **p < 0.01. Floating box extends from 25th to 75th percentiles, line through the box indicates median, and bars extend from the smallest to largest values. d Kaplan-Meier survival curves for disease-free survival according to the expression of CD44v6 at baseline in ONCOFID-B-P™-treated bladder CIS patients. The median cut-off of each variable was used to separate high and low groups. Log-rank p values, hazard ratios (HR) and 95% confidence intervals (CI) are reported in the graph. e Correlation between CD44v6 expression and the density of total (Spearman r = 0.5193 95% CI 0.07 to 0.79; p = 0.022) or intra-tumoral CD68+ macrophages (r = 0.54 95% CI 0.09 to 0.80; p = 0.016). f Kaplan-Meier curves for disease-free survival stratifying patients according to the expression of CD44v6 and the intra-tumoral CD68 density. The median value of each variable was used as cut-off to identify high and low subgroups. Log-rank p values, hazard ratios (HR) and 95% confidence intervals (CI) are reported in each graph. g Receiving Operator Curve (ROC) showing the performance of the combined CD44v6 expression and intra-tumoral CD68+ cells to predict patient response to ONCOFID-P-B™